Significant benefits of pembrolizumab in treating refractory advanced pulmonary sarcomatoid carcinoma: A case report

doi:10.12998/wjcc.v8.i13.2876

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 8, Issue 13

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (6392)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-4) series.

Item

Count

PDF

461

WORD

106

HTML

3500

Figures (1-4)

302

Sum=4369

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

758

Download

1265

Sum=2023

Jul 6, 2020 (publication date) through Nov 4, 2024

Times Cited of This Article

Times Cited (6)

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Case Report

World J Clin Cases. Jul 6, 2020; 8(13): 2876-2884
Published online Jul 6, 2020. doi: 10.12998/wjcc.v8.i13.2876

Full Size Figure Download Figure

Figure 3 Sequence of antitumor treatments across the timeline. TC: Paclitaxel plus carboplatin; WBRT: Radiotherapy to the right chest wall.

Citation: Chen P, Yu M, Zhang JL, Chen WY, Zhu L, Song Y, Jiang CY, Zhang S. Significant benefits of pembrolizumab in treating refractory advanced pulmonary sarcomatoid carcinoma: A case report. World J Clin Cases 2020; 8(13): 2876-2884
URL: https://www.wjgnet.com/2307-8960/full/v8/i13/2876.htm
DOI: https://dx.doi.org/10.12998/wjcc.v8.i13.2876